indications for glp 1 agonists Nutritional priorities to support GLP-1 therapy obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society The expanding benefits of GLP-1

Their smaller molecular structure also facilitates better tissue penetration and lower production costs, which could enhance accessibility to these novel medications

Dual agonist: GLP-1 plus GIP: Tirzapeptide is a combination of GLP-1 RA and a GIP agonist that is FDA-approved for weight loss

Adverse Events Related to Tirzepatide

Some common side effects may include mild nausea, vomiting, or digestive discomfort, especially during the initial stages of treatment

[DOI] [PMC free article] [PubMed] [Google Scholar] 80.Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr., et al

This makes it easier for our patients to reduce caloric intake and achieve their weight loss goals